| Literature DB >> 25281593 |
Pedro J Alcolea1, Ana Alonso, Manuel J Gómez, Marina Postigo, Ricardo Molina, Maribel Jiménez, Vicente Larraga.
Abstract
BACKGROUND: Leishmania infantum is the etiological agent of zoonotical visceral leishmaniasis in the Mediterranean basin. A recent outbreak in humans has been recently reported in central Spain. Leishmania spp. parasites are transmitted to the mammalian host by the bite of sand flies. The primary vector of L. infantum in Spain is Phlebotomus perniciosus. For decades, research on these parasites has involved the axenic culture model of the promastigote stage including gene expression profiling studies performed in the post-genome era. Unlike the controversial axenic culturing of amastigotes, promastigote cultures are generally accepted and used, although with the precaution of avoiding excessive culture passage.The primary objective of this differentiation study is to compare the gene expression profiles of promastigotes isolated from the foregut of the sand fly and amastigotes. For this purpose, P. perniciosus sand flies were infected with L. infantum and differentiated promastigotes were extracted by dissection of the foreguts. Shotgun DNA microarray hybridization analyses allowed for transcriptome comparison of these promastigotes with amastigotes obtained by infection of the U937 cell line. The results have been compared with those described in published expression analyses using axenic promastigotes.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25281593 PMCID: PMC4203910 DOI: 10.1186/1471-2164-15-849
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Sampling and mRNA amplification. (A) The life cycle of Leishmania spp. (B) Promastigote RNA extraction was performed immediately after dissection of the sand fly guts and mild lysis of U937 cells. Pro-Pper samples were immediately washed in PBS and lysed with TRIzol® for total RNA extraction. After that, mRNA was doubly amplified (aaRNA) due to sample amount requirements. This included two cycles of reverse transcription (RT) plus second strand cDNA synthesis (combining the use of the Klenow fragment and the RNase H) plus in vitro transcription (IVT). The RT reaction of the first amplification round was performed with a poly-dT primer and the second strand synthesis and the RT reaction of the second amplification round were performed with random hexamer primers, all of which were provided in the MessageAmpTM II aRNA Amplification Kit. Three biological replicates were obtained to perform the subsequent microarray experiment. (C) Electrophoresed aaRNA samples used for the microarray analysis after synthesis of labeled cDNA.
Figure 2General outcome of the Pro-Pper/A microarray hybridization experiment in . M/A scatter plot of hybridization outcomes of all clones fulfilling (highlighted) or not the conditions necessary for containing differentially regulated genes between Pro-Pper and Amas. M = (log2Ri – log2Gi) and A = [(log2Ri + log2Gi)/2], where R and G are, respectively, red (Cy5) and green (Cy3) fluorescence intensity values. Red spots correspond to selected DNA fragments containing a gene up-regulated by at least 2-fold and green spots represent those down-regulated by at least 2-fold times. Further criteria for spot selection are detailed in the Methods section.
Overview of the Pro-Pper/A differential gene expression profiles
| Annotation status | Frequency of differentially regulated genes in Pro-Pper/A | |
|---|---|---|
| Up-regulated | Down-regulated | |
| Genes of known function | 46 | 19 |
| Conserved hypothetical protein | 48 | 25 |
| Hypothetical protein | 4 | 1 |
| Clones overlapping with UTRs or less than 5% of an ORF (Additional file | 86 | 48 |
| Total (n = 277) | 184 | 93 |
Absolute frequencies of genes encoding for proteins of known function and hypothetical proteins are provided. The frequencies of up-regulated and down-regulated genes have been contrasted with the binomial test.
Genes of known function that are differentially regulated in Pro-Pper with respect to amastigotes
|
|
|
|
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
| |||||||||
| Lin13C3 | 2.72 | 1.4 ± 0.3 | 0.011 | 0 | 0 | b | LinJ.21.0770 | Ribonuclease-L inhibitor, ABC subfamily E, putative | N.D. | |
| Lin16F1 | 3.69 | 1.9 ± 0.4 | 0.014 | - | 0 | c | LinJ.23.0050 | Peroxidoxin/tryparredoxin peroxidase | N.D. | |
| Lin16C2 | 24.97 | 4.6 ± 0.5 | 0.004 | 0 | 0 | b | LinJ.35.3930 | EF-hand calmodulin-like protein | + | 65.3 ± 3.1 |
| LinJ.35.3940 | Hypothetical protein, conserved | N.D. | ||||||||
| Lin17G12 | 2.49 | 1.3 ± 0.4 | 0.034 | 0 | 0 | a | LinJ.19.0940 | 4-coumarate-CoA ligase | N.D. | |
| Lin21H10 | 17.97 | 4.2 ± 1.0 | 0.019 | 0 | 0 | b | LinJ.26.1670 | Sphingolipid δ-4 desaturase, putative | + | 4.1 ± 0.3 |
| Lin22C9 | 2.14 | 1.1 ± 0.4 | 0.040 | 0 | 0 | b | LinJ.33.2910 | Ubiquitin-conjugating enzyme, putative | N.D. | |
| 27C6 | 4.17 | 2.1 ± 0.2 | 0.002 | 0 | 0 | a | LinJ.31.1240 | Vacuolar H+-translocating pyrophosphatase, putative | N.D. | |
| Lin28C5 | 7.31 | 2.9 ± 0.6 | 0.020 | 0 | 0 | b | LinJ.26.1670 | Sphingolipid δ-4 desaturase, putative | + | 4.1 ± 0.3 |
| Lin31D11 | 3.00 | 1.6 ± 0.3 | 0.016 | 0 | 0 | b | LinJ.31.1870 | Protein kinase-like protein | N.D. | |
| Lin34F1 | 2.98 | 1.6 ± 0.5 | 0.038 | LinJ.08.1000 | Histone deacetylase, putative | N.D. | ||||
| LinJ.26.1620 | 40S ribosomal protein S33, putative | + | 92.2 ± 5.2 | |||||||
| LinJ.26.1630 | 40S ribosomal protein S33, putative | + | 92.2 ± 5.2 | |||||||
| LinJ.26.1640 | Hypothetical protein, conserved | N.D. | ||||||||
| Lin41C12 | 2.95 | 1.6 ± 0.5 | 0.028 | 0 | 0 | b | LinJ.31.1600 | Cytochrome c oxidase VIII (coxVIII), putative | N.D. | |
| Lin45A11 | 2.35 | 1.2 ± 0.4 | 0.033 | 0 | 0 | b | LinJ.28.2220 | Mitochondrial DEAD protein, putative | N.D. | |
| Lin48B6 | 2.60 | 1.4 ± 0.4 | 0.026 | 0 | 0 | b | LinJ.36.2050 | Mismatch repair protein MSH8, putative | N.D. | |
| Lin49B7 | 9.21 | 3.2 ± 1.1 | 0.039 | 0 | 0 | b | LinJ.06.1320 | Pteridin transporter, putative | N.D. | |
| Lin50G5 | 3.83 | 1.9 ± 0.4 | 0.016 | 0 | 0 | a | LinJ.21.2080 | Cytochrome oxidase VI (coxVI), putative | N.D. | |
| Lin51A8 | 2.24 | 1.2 ± 0.4 | 0.041 | 0 | 0 | a | LinJ.32.4190 | GIPL-galf transferase, putative | N.D. | |
| Lin51E2 | 2.09 | 1.1 ± 0.2 | 0.018 | 0 | 0 | b | LinJ.36.0020 | Histone H4 | N.D. | |
| Lin51G7 | 3.85 | 1.9 ± 0.2 | 0.003 | 0 | 0 | b | LinJ.19.1490 | Oxidoreductase-like protein | + | 3.6 ± 0.2 |
| LinJ.19.1500 | Hypothetical protein, conserved | N.D. | ||||||||
| Lin54C2 | 7.13 | 2.8 ± 0.5 | 0.010 | 0 | 0 | a | LinJ.06.1310 | Mitogen-activated protein kinase | + | 10.8 ± 0.5 |
| LinJ.06.1320 | Hypothetical protein, conserved | N.D. | ||||||||
| LinJ.06.1330 | Hypothetical protein, conserved | N.D. | ||||||||
| Lin58H6 | 5.43 | 2.4 ± 1.0 | 0.049 | 0 | 0 | b | LinJ.08.0030 | Vesicle-associated membrane protein, putative | N.D. | |
| Lin60H10 | 4.41 | 2.1 ± 0.2 | 0.003 | 0 | 0 | a | LinJ.23.0630 | Oxidoreductase-like protein | + | 2.9 ± 0.1 |
| Lin76A1 | 3.08 | 1.6 ± 0.4 | 0.018 | 0 | 0 | a | LinJ.31.3320 | Histone H4 | + | 11.0 ± 0.4 |
| Lin76F1 | 5.40 | 2.4 ± 0.5 | 0.013 | 0 | 0 | b | LinJ.34.3370 | Phosphatidylinositol 4-kinase, putative | N.D. | |
| Lin77B12 | 2.01 | 1.0 ± 0.3 | 0.038 | 0 | 0 | a | LinJ.27.1520 | Eukaryotic translation initiation factor eIF4E, putative | N.D. | |
| Lin80B3 | 2.83 | 1.5 ± 0.6 | 0.049 | 0 | 0 | b | LinJ.28.3250 | Glucose-6-phosphate N-acetyltransferase, putative | N.D. | |
| Lin82D10 | 4.25 | 2.1 ± 0.5 | 0.019 | 0 | 0 | a | LinJ.23.0040 | β -propeller, putative | + | 2.0 ± 0.1 |
| LinJ.23.0050 | Peroxidoxin/Tryparedoxin peroxidase | + | 21.2 ± 0.8 | |||||||
| LinJ.23.0060 | Cyclophilin, putative | N.D. | ||||||||
| Lin89D8 | 2.87 | 1.5 ± 0.4 | 0.023 | 0 | 0 | a | LinJ.36.3230 | Lipoate protein ligase, putative | + | 8.0 ± 0.5 |
| Lin93D6 | 5.50 | 2.5 ± 0.3 | 0.005 | 0 | 0 | b | LinJ.26.1670/80 | Sphingolipid δ-4 desaturase, putative | + | 4.1 ± 0.4 |
| LinJ.26.1690 | Cytochrome c oxidase, subunit V (coxV), putative | N.D. | ||||||||
| Lin96H7 | 4.92 | 2.3 ± 0.3 | 0.007 | 0 | 0 | a | LinJ.31.3310 | Hypothetical protein, unknown function | N.D. | |
| LinJ.31.3320 | Histone H4, putative | + | 11.0 ± 0.4 | |||||||
| Lin96B8 | 4.21 | 2.1 ± 0.8 | 0.046 | 0 | 0 | a | LinJ.31.3310 | Hypothetical protein, unknown function | N.D. | |
| LinJ.31.3320 | Histone H4, putative | + | 11.0 ± 0.4 | |||||||
| Lin99G6 | 4.02 | 2.0 ± 0.5 | 0.002 | 4e-156 | 9e-80 | b | LinJ.36.1730 | Proteasome subunit β5, putative | + | 5.2 ± 0.2 |
| Lin105H8 | 3.92 | 2.0 ± 0.6 | 0.026 | 0 | 0 | b | LinJ.36.3750 | Cysteine synthase, putative | + | 3.6 ± 0.0 |
| Lin106G3 | 2.26 | 1.2 ± 0.3 | 0.029 | 0 | 0 | a | LinJ.31.1070 | Biotin/lipoate-protein ligase | + | 8.0 ± 0.5 |
| Lin110F5 | 3.55 | 1.8 ± 0.3 | 0.011 | 0 | 0 | a | LinJ.16.1220 | 60S ribosomal protein L39, putative | N.D. | |
| Lin111D8 | 9.80 | 3.3 ± 0.8 | 0.020 | 0 | 0 | a | LinJ.08.1000 | Histone deacetylase, putative | N.D. | |
| Lin113B9 | 2.72 | 1.4 ± 0.6 | 0.048 | 0 | 0 | a | LinJ.36.0550 | Hypothetical protein, conserved | N.D. | |
| LinJ.36.0560 | Protein phosphatase 2C, putative | + | 6.4 ± 0.2 | |||||||
| LinJ.36.0570 | Small nuclear ribonucleoprotein, putative | + | 9.4 ± 0.8 | |||||||
| Lin125F11 | 5.88 | 2.5 ± 1.0 | 0.046 | 7e-56 | 3e-55 | a | LinJ.32.2780 | Cistathionine γ-liase, putative | N.D. | |
| Lin130C5 | 2.52 | 1.3 ± 0.5 | 0.040 | 3e-178 | 0 | b | LinJ.36.3170 | Exosome exonuclease RRP41, putative | - | -3.3 ± 0.2 |
| LinJ.36.3180 | Clathrin coat assembly protein | N.D. | ||||||||
| LinJ.36.3190 | Pre-mRNA branch site p14 protein, putative | + | 43.2 ± 1.3 | |||||||
| LinJ.36.3200 | Hypothetical protein, conserved | N.D. | ||||||||
| Lin132A11 | 5.24 | 2.4 ± 0.1 | 0.001 | 0 | 0 | a | LinJ.31.1240 | Vacuolar H+-translocating pyrophosphatase, putative | N.D. | |
| Lin136G4 | 2.66 | 1.4 ± 0.6 | 0.049 | 0 | 0 | b | LinJ.22.1360 | Hypothetical protein, conserved | N.D. | |
| LinJ.22.1370 | 60S ribosomal protein L14, putative | + | 4.1 ± 0.3 | |||||||
| Lin139D8 | 5.85 | 2.5 ± 0.6 | 0.003 | 0 | 0 | b | LinJ.08.0010 | Structural maintenance of chromosome protein 3, putative | N.D. | |
| Lin146A12 | 2.67 | 1.4 ± 0.4 | 0.032 | 0 | 0 | b | LinJ.30.0710 | 40S ribosomal protein S30, putative | + | 56.2 ± 1.7 |
| LinJ.30.0720 | NUDC-like protein | N.D. | ||||||||
| Lin166F2 | 5.54 | 2.5 ± 0.7 | 0.023 | 0 | 0 | b | LinJ.21.0770 | Ribonuclease -L inhibitor, ABC subfamily E, putative | N.D. | |
| Lin166H10 | 2.08 | 1.1 ± 0.2 | 0.014 | 0 | 0 | b | LinJ.26.1680 | Sphingolipid δ-4 desaturase, putative | + | 4.1 ± 0.4 |
| LinJ.26.1690 | Cytochrome b5 reductase, putative | N.D. | ||||||||
| Lin168F2 | 2.17 | 1.1 ± 0.2 | 0.017 | 0 | 0 | a | LinJ.32.0710 | OSM-3-like kinesin | N.D. | |
| Lin169E6 | 6.66 | 2.7 ± 0.9 | 0.037 | 0 | 0 | b | LinJ.32.0550 | Profilin, putative | N.D. | |
| Lin172B9 | 4.42 | 2.1 ± 0.4 | 0.009 | 0 | 0 | b | LinJ.26.1680 | Sphingolipid δ-4 desaturase, putative | + | 4.1 ± 0.4 |
| LinJ.26.1690 | Cytochrome b5 reductase, putative | N.D. | ||||||||
| Lin208F7 | 3.33 | 1.7 ± 0.6 | 0.033 | 0 | 0 | b | LinJ.30.3640 | Ser/Thr protein kinase, putative | N.D. | |
| Lin276F6 | 3.47 | 1.8 ± 0.3 | 0.007 | 0 | 0 | b | LinJ.35.2370 | Protein kinase, putative | N.D. | |
| Lin290F2 | 3.52 | 1.8 ± 0.3 | 0.012 | 0 | 0 | b | LinJ.04.1250 | Actin | N.D. | |
| Lin298H2 | 7.23 | 2.8 ± 0.5 | 0.011 | 0 | 0 | b | LinJ.22.1340 | Ser/Thr protein phosphatase | N.D. | |
| Lin299A1 | 4.34 | 2.1 ± 0.8 | 0.045 | 0 | 0 | b | LinJ.36.1720 | Universal minicircle sequence binding protein (UMSBP), putative | N.D. | |
| Lin18A12 | -2.20 | -1.1 ± 0.4 | 0.044 | 0 | 0 | b | LinJ.33.2430 | UDP-glucose 4′-epimerase | N.D. | |
| Lin25B7 | -2.34 | -1.2 ± 0.4 | 0.034 | 0 | 0 | b | LinJ.31.3390 | Sodium stibogluconate resistance protein | N.D. | |
| Lin30H4 | -3.45 | -1.8 ± 0.4 | 0.017 | 0 | 2e-111 | b | LinJ.27.2500 | Glycosomal phosphoenolpyruvate carboxykinase, putative | N.D. | |
| Lin35H4 | -2.77 | -1.5 ± 0.5 | 0.039 | 0 | 0 | b | LinJ.34.3740 | Expression-site associated glycoprotein (ESAG5), putative | N.D. | |
| Lin49D6 | -2.83 | -1.5 ± 0.5 | 0.031 | 0 | 1e-152 | b | LinJ.19.0590 | Protein kinase, putative | N.D. | |
| Lin54A3 | -2.21 | -1.1 ± 0.4 | 0.037 | 4e-156 | 0 | b | LinJ.36.6510 | Small G protein, putative | N.D. | |
| Lin77H8 | -2.07 | -1.0 ± 0.4 | 0.039 | 0 | 0 | b | LinJ.08.0690 | Amastin-like protein | N.D. | |
| Lin88B2 | -2.08 | -1.1 ± 0.4 | 0.040 | 0 | 0 | b | LinJ.10.1070 | Histone H3 | N.D. | |
| Lin101D5 | -2.54 | -1.3 ± 0.3 | 0.017 | 0 | 2e-28 | b | LinJ.27.2500 | Glycosomal phosphoenolpyruvate carboxykinase, putative | N.D. | |
| Lin101E5 | -2.71 | -1.4 ± 0.5 | 0.046 | 0 | 0 | b | LinJ.35.5330 | Protein kinase, putative | N.D. | |
| Lin107B10 | -2.22 | -1.1 ± 0.3 | 0.003 | 0 | 0 | b | LinJ.06.1110 | Deoxyribose phosphate aldolase, putative | + | -7.3 ± 0.6 |
| LinJ.06.1120 | Hypothetical protein, conserved | N.D. | ||||||||
| Lin115H5 | -2.37 | -1.2 ± 0.4 | 0.034 | 0 | 3e-136 | b | LinJ.03.0790 | 6-phosphofructo-2-kinase/fructose-2,6-diphosphatase, putative | N.D. | |
| Lin123E6 | -2.11 | -1.1 ± 0.3 | 0.019 | 0 | 0 | b | LinJ.23.0980 | Actin-interacting protein | N.D. | |
| Lin188B12 | -2.46 | -1.3 ± 0.1 | 0.001 | 0 | 0 | b | LinJ.31.3400 | Sodium stibogluconate-resistance protein | N.D. | |
| Lin286D1 | -2.41 | -1.3 ± 0.4 | 0.035 | 0 | 0 | b | LinJ.08.1320 | Amastin-like protein | N.D. | |
| Lin274G6 | -2.25 | -1.2 ± 0.4 | 0.037 | 0 | 0 | b | LinJ.08.0680/90 | Amastin-like protein | N.D. | |
| Lin283F3 | -2.12 | -1.1 ± 0.3 | 0.023 | 0 | 0 | b | LinJ.15.0130 | ATP-dependent RNA helicase, putative | N.D. | |
| Lin283H1 | -2.60 | -1.4 ± 0.2 | 0.010 | 0 | 0 | b | LinJ.21.1670 | 2-oxoisovalerate dehydrogenase, subunit α, putative | N.D. | |
| Lin308D6 | -2.11 | -1.1 ± 0.1 | 0.002 | 0 | 0 | b | LinJ.11.0060 | Protein kinase, putative | N.D. | |
Fold changes (up-regulation if F > 2, over the dividing line, and down-regulation if F < -2, below the dividing line), base-two logarithmic scale F and their SD, p, e-values, clone definitions according to mapping outcomes a, b and c, Ids. and annotated functions in the L. infantum genome sequence and the qRT-PCR outcomes are provided. When a given clone overlaps with more than one annotation, only the clones checked for differential regulation using qRT-PCR and non-resolved clones overlapping with resolved clones containing a common gene appear in this table.
Figure 3Biological process multi-level bar graph for GO terms annotated with BLAST2GO.
Figure 4Schema illustrating the scenario of the relative expression profiles of Pro-Pper and amastigotes. Protein products of regulated genes in Pro-Pper/A are represented in red and those of down-regulated genes in green. Blue arrows highlight the hypothesis for an important role for the BLPL, which may be specifically regulated to achieve any of the processes indicated. Differentially regulated genes related to signal transduction: calmodulin-like EF-hand protein, MAPKs, PI4K, PKs, PP2C, Ser/Thr PPase, small G protein. Differentially regulated genes related to cytoskeleton remodeling: actin microfilament, AIP, coronin, α-tubulin isoform.
Figure 5Comparison of the whole genome gene expression profile of amastigotes using Pro-Pper or cultured promastigotes as reference. The profiles of cultured logarithmic and stationary phase promastigotes compared with amastigotes have been published [23]. (A) Venn diagrams contrasting differential gene expression in L. infantum amastigotes depending on the origin of promastigotes. (B) Relative expression and classification (MEV analysis) in clusters of genes showing similar patterns or opposite expression profiles in amastigotes depending on the source of promastigotes (see a complete overview of the clustering analysis in Additional file 5).